

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	13034340
	Filing Date	2011-02-24
	First Named Inventor	Alan H. Auerbach
	Art Unit	1621
	Examiner Name	San Ming R. Hui
	Attorney Docket Number	CGR5001USCNT1

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20060030608	A1	2006-02-09	Nelson, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2478907	EP		2012-07-25	Cougar Biotechnology, Inc.		<input type="checkbox"/>
	2	2006027266	WO		2006-03-16	Nitec Pharma AG		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS								
---------------------------------	--	--	--	--	--	--	--	--

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	13034340
Filing Date	2011-02-24
First Named Inventor	Alan H. Auerbach
Art Unit	1621
Examiner Name	San Ming R. Hui
Attorney Docket Number	CGR5001USCNT1

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Assessment Report for Zytiga (abiraterone) published 2011 by the CHMP of the EMA	<input type="checkbox"/>
	2	AUCHUS, R.J., "The genetics, pathophysiology, and the management of human deficiencies of P450c17", Endocrinol Metab Clin North Am (2001), 30, p.101-119	<input type="checkbox"/>
	3	AYUB, M., "Inhibition of testicular 17a-hydroxylase and 17,20-lyase but not 3B-hydroxysteroid dehydrogenase-isomerase or 17B-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs, Journal of Steroid Biochemistry (1987) 28(5), p.521-531	<input type="checkbox"/>
	4	Campbell-Walsh Urology, Ninth Edition, Saunders, Vol. 3, Chapters 104 and 105	<input type="checkbox"/>
	5	Cecil Textbook of Medicine, Wyngaarden & Smith 18th edition; Chapter on "Glucocorticosteroid Therapy", Wyngaarden & Smith 18th edition, (1988) p.128-131	<input type="checkbox"/>
	6	Cougar Biotechnology Inc. with the U.S. Securities and Exchange Commission, Form 10-QSB	<input type="checkbox"/>
	7	CZOCK, et al., "Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids", Pharmacokinet (2005), 44(1), p.61-98	<input type="checkbox"/>
	8	ERGUN-LONGMIRE, Berrin, et al., "Two Novel Mutations Found in a Patient with 17a-Hydroxylase Enzyme Deficiency", The Journal of Clinical Endocrinology & Metabolism (2006), 91(10), p.4179-4182	<input type="checkbox"/>
	9	FAKIH, et al., Urology (2002) 60, p.553-561	<input type="checkbox"/>
	10	FRIEL, Patrick N., et al., "Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles-A review of five cases", Alternative Medicine Review (2006), 11(1)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	13034340
Filing Date	2011-02-24
First Named Inventor	Alan H. Auerbach
Art Unit	1621
Examiner Name	San Ming R. Hui
Attorney Docket Number	CGR5001USCNT1

11	Internet article: http://clinicaltrials.gov/archive/NCT00485303/2007_06_11	<input type="checkbox"/>
12	Information concerning Zytiga (abiraterone acetate) from http://www.kompndium.ch/prod/pnr/1183238/de?Platform=Desktop as of March 25, 2014	<input type="checkbox"/>
13	Internet article: http://clinicaltrials.gov/ct2/show/study/NCT00485303?sec=X501	<input type="checkbox"/>
14	MOSTAGHEL, E.A., "Abiraterone in the treatment of metastatic castration-resistant prostate cancer", <i>Cancer Management Res.</i> (2014) 6, p.39-51	<input type="checkbox"/>
15	OSABA, D., et al., "Health-Related Quality of Life in Men with Metastatic Prostate Cancer Treated with Prednisone alone or Mitoxantrone and Prednisone", <i>J. Clin. Oncol.</i> (1999), 17(6), p.1654-1663	<input type="checkbox"/>
16	PETRYLAK, D.P., "New Paradigms for Advanced Prostate Cancer", <i>Rev. Urol.</i> (2007), 9, Suppl. 2, S3-S12	<input type="checkbox"/>
17	Prostate Cancer Principles and Practice, Taylor & Francis (2006) Chapter 93	<input type="checkbox"/>
18	REID, A., et al., "Annals of Oncology", Educational and Abstract Book of the ESMO Conference Lugano (ECLU), (2007), 18(Supplement 9), ix173-ix174. Abstract 50PD	<input type="checkbox"/>
19	REMINGTON, "The Science and Practice of Pharmacy, 20th Edition (2000), p.1363-1370	<input type="checkbox"/>
20	RUNGE, Marschall S., et al., "Principles of Molecular Medicine; Second edition; (2006) Humana Press Inc. ISBN: 1-58829-202-9. pgs.365-376 and 482-484	<input type="checkbox"/>
21	SILLS, Irene N., et al., "17a-hydroxylase deficiency in a genetic male and female sibling pair", <i>Int. J. Gynaecol. Obstet.</i> (1981), 19, p.473-479	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	13034340
Filing Date	2011-02-24
First Named Inventor	Alan H. Auerbach
Art Unit	1621
Examiner Name	San Ming R. Hui
Attorney Docket Number	CGR5001USCNT1

22	Summary of Product Characteristics for Zytiga 250mg tablets (16Jan2014)	<input type="checkbox"/>
23	TANNOCK., et al., "Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer", Journal of Urology (2005), 173(2), p.456	<input type="checkbox"/>
24	The reply of applicant (i.e. the Proprietor of herein opposed patent) dated June 4, 2013 in relation to the corresponding US2011/0144016A1 US proceedings.	<input type="checkbox"/>
25	WANG, C., et al., "Hypertension due to 17a-Hydroxylase deficiency", Australian and New Zealand Journal of Medicine (1978), 8(3), p.295-299	<input type="checkbox"/>
26	YANO, A., et al., "Glucocorticoids Suppress Tumor Angiogenesis and In vivo Growth of Prostate Cancer Cells", Clin. Cancer Res., (2006) 12, 3003-3009	<input type="checkbox"/>
27		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.